Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end ‐stage of renal disease

ConclusionsWe found that SV could safely reduce the hsTnT and sST2 levels and improve LVEF in HFrEF patients with ESRD. As far as we know, this is the first study to show the efficacy and safety of SV in HFrEF with ESRD on dialysis. Larger prospective, long ‐term follow‐up study should be warranted.

Source: ESC Heart Failure - March 10, 2020 Category: Cardiology Authors: Seonhwa Lee, Jaewon Oh, Hyoeun Kim, Jaehyung Ha, Kyeong ‐hyeon Chun, Chan Joo Lee, Sungha Park, Sang‐Hak Lee, Seok‐Min Kang Tags: Short Communication Source Type: research